Researchers are advancing a recombinant flu vaccine that uses innovative nanoliposome technology for enhanced immunity and efficiency, showing promising early results against common flu strains. Credit: SciTechDaily.comRecombinant protein vaccines, like the Novavax vaccine used to fightThey’re easy to precisely produce. They’re safe, and potentially more effective. And they could require smaller doses.
Conventional flu vaccines contain either deactivated microbes that cause influenza or are based on weakened forms of the disease. They are made using fertilized chicken eggs or, less commonly, through cell culture-based production.The vaccine the UB-led team is developing is based on a nanoliposome – a tiny spherical sac – that Lovell and colleagues created called cobalt-porphyrin-phospholipid, or CoPoP.
Even when administered in low doses, the hexaplex nanoliposome provided superior protection and survival from H1 and N1 when compared to Flublok, which is the sole licensed recombinant influenza vaccine in the U.S., and Fluaid, an egg-based vaccine. Tests showed comparable levels of protection against H3N2 and type B viruses.
Bruce Davidson, PhD, research associate professor of anesthesiology in the Jacobs School of Medicine and Biomedical Sciences at UB, is a senior co-author of the study.
Technology Technology Latest News, Technology Technology Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ABC7NY - 🏆 592. / 51 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: Crypto_Potato - 🏆 568. / 51 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »